Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.
Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab
July 25, 2018
Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet
July 17, 2018
The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina
June 18, 2018
Glenmark Pharmaceuticals Announces Poster Presentations on GBR 1302 and GBR 1342, HER2xCD3 and CD38xCD3 Bispecific Antibodies, at the 2018 ASCO Annual Meeting
May 25, 2018
US Media Contact
For media inquiries only, please contact An Phan, Corporate Communications.
For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.